{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:57:56Z","timestamp":1788494276190,"version":"build-2803163510"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ23H160041"],"award-info":[{"award-number":["LQ23H160041"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>This study aims to compare the safety and efficiency of modified biweekly CAPOX and conventional triweekly CAPOX in high-risk stage II and stage III post-surgery colorectal (CRC) patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>From July 25, 2018, to May 14, 2021, high-risk stage II and stage III post-surgery CRC patients were randomized in the control triweekly group (intravenous infusion of oxaliplatin 130\u2009mg\/m<jats:sup>2<\/jats:sup> on day 1 and oral capecitabine 1000\u2009mg\/m<jats:sup>2<\/jats:sup>, twice daily from day 1 to day 14) and the experimental biweekly group (intravenous infusion of oxaliplatin 85\u2009mg\/m<jats:sup>2<\/jats:sup> on day 1 and oral capecitabine 1000\u2009mg\/m<jats:sup>2<\/jats:sup>, twice daily from day 1 to day 10). The primary endpoint was the incidence rate of thrombocytopenia. The secondary endpoint was 3-year disease free survival (DFS) rate. The patients follow up was started on July 25, 2018, and finished on October 8, 2024.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 160 patients were 1:1 randomly assigned (80 patients to biweekly group and 80 patients to triweekly group). All grade thrombocytopenia occurred in 33% and 49% patients at biweekly and triweekly group, respectively (<jats:italic>P\u2009<\/jats:italic>=\u20090.02). Neutropenia presented in 36% and 51% patients at biweekly and triweekly group, respectively (<jats:italic>P\u2009<\/jats:italic>=\u20090.04). The second endpoint 3-year DFS was 85.1% in biweekly group and 80.4% in triweekly CAPOX group (<jats:italic>P\u2009<\/jats:italic>=\u20090.51, HR\u2009=\u20090.78, [95%CI, 0.38\u20131.63]). The total rate of uncomplete therapy patient was 7.5% and 15% in biweekly and triweekly group, respectively (<jats:italic>P\u2009<\/jats:italic>=\u20090.13).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Biweekly CAPOX presented significant less thrombocytopenia and neutropenia than triweekly CAPOX regimen. There was no difference in 3-year DFS between biweekly CAPOX and triweekly CAPOX.<\/jats:p>\n<jats:p><jats:bold>Clinical trial registration:<\/jats:bold> ClinicalTials.gov (NCT03564912).<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0313472","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:38:28Z","timestamp":1752255508000},"page":"e0313472","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-3915","authenticated-orcid":true,"given":"Hangyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"6","key":"pone.0313472.ref001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"pone.0313472.ref002","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/bjc.2016.177","article-title":"Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England","volume":"115","author":"S Benitez-Majano","year":"2016","journal-title":"Br J Cancer"},{"issue":"23","key":"pone.0313472.ref003","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"T Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"issue":"32","key":"pone.0313472.ref004","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial","volume":"33","author":"H-J Schmoll","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0313472.ref005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2020.10.480","article-title":"Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial","volume":"32","author":"K Yamazaki","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"pone.0313472.ref006","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdz193","article-title":"Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project","volume":"30","author":"J Souglakos","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"pone.0313472.ref007","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.20.01330","article-title":"Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer","volume":"39","author":"TJ Iveson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"33","key":"pone.0313472.ref008","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.21.02962","article-title":"Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II\/III colon cancer: KCSG CO09-07","volume":"40","author":"ST Kim","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"pone.0313472.ref009","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer","volume":"29","author":"DG Haller","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0313472.ref010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jgo.2013.01.001","article-title":"Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer","volume":"4","author":"C Grande","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"pone.0313472.ref011","first-page":"3437","article-title":"Bi-weekly capecitabine-oxaliplatin (XELOX) plus bevacizumab as first-line treatment of metastatic colorectal cancer -the PHOENiX trial","volume":"36","author":"T Matsui","year":"2016","journal-title":"Anticancer Res"},{"issue":"13","key":"pone.0313472.ref012","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"A Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0313472.ref013","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00280-014-2407-y","article-title":"A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer","volume":"73","author":"Y Chao","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"36","key":"pone.0313472.ref014","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1200\/JCO.2008.16.7759","article-title":"Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil\/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials","volume":"26","author":"H-T Arkenau","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0313472.ref015","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"CM Nielson","year":"2021","journal-title":"Oncologist"},{"issue":"34","key":"pone.0313472.ref016","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.21.01032","article-title":"Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial","volume":"39","author":"Y Kanemitsu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0313472.ref017","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000354","article-title":"Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer","volume":"3","author":"M Kotaka","year":"2018","journal-title":"ESMO Open"},{"issue":"11","key":"pone.0313472.ref018","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jamaoncol.2019.2572","article-title":"Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial","volume":"5","author":"T Yoshino","year":"2019","journal-title":"JAMA Oncol"},{"issue":"18","key":"pone.0313472.ref019","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1200\/JCO.23.01648","article-title":"Prognostic and predictive value of immunoscore in stage III colorectal cancer: pooled analysis of cases from the SCOT and IDEA-HORG studies","volume":"42","author":"E Domingo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"33","key":"pone.0313472.ref020","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1200\/JCO.24.00393","article-title":"Extent of lymphadenectomy for surgical management of right-sided colon cancer: the randomized phase III RELARC trial","volume":"42","author":"J Lu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0313472.ref021","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1308\/rcsann.2021.0049","article-title":"Colorectal cancer in the young - outcomes following surgical management?","volume":"103","author":"L Newton","year":"2021","journal-title":"Ann R Coll Surg Engl"},{"issue":"10","key":"pone.0313472.ref022","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1470-2045(22)00506-X","article-title":"Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis","volume":"23","author":"BL Ecker","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0313472.ref023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"D Kotani","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"pone.0313472.ref024","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41416-022-02017-9","article-title":"The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis","volume":"128","author":"LG Faulkner","year":"2023","journal-title":"Br J Cancer"},{"issue":"3","key":"pone.0313472.ref025","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000005755","article-title":"Negative prognostic impact of tumor deposits in rectal cancer: a national study cohort","volume":"278","author":"E Agger","year":"2023","journal-title":"Ann Surg"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:38:36Z","timestamp":1752255516000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313472"}},"subtitle":[],"editor":[{"given":"Keun-Yeong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313472","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}